By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Food and Drug Administration has issued two new guidances affecting genomic technologies and genetic testing, including one detailing its policies for making risk-based assessments of medical devices, and another covering the process for the submission of genomic biomarkers for qualification by regulatory authorities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.